Clinical Trials on Bruton's Tyrosine Kinase in Korea, Democratic People's Republic of

Total 14 results

Astellas Pharma Korea, Inc.

Recruiting

A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

Korea, Republic of
Samsung Medical Center

Active, not recruiting

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

Non-Small Cell Lung Cancer With EGFR T790M Mutation | With Brain and/or Leptomeningeal Metastasis | Failed Tyrosine Kinase Inhibitors

Korea, Republic of
Takeda

Recruiting

A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea

Carcinoma, Non-Small-Cell Lung | Anaplastic Lymphoma Kinase

Korea, Republic of
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

United States, Japan, Taiwan, Spain, Australia, Belgium, Canada, France, Germany, Italy, Korea, Republic of, Poland, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation

Taiwan, Poland, Serbia, United States, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Romania, Spain, Sweden, United Kingdom
Blueprint Medicines Corporation

Active, not recruiting

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | EGF-R Positive Non-Small Cell Lung... and other conditions

United States, Canada, Taiwan, Korea, Republic of, Singapore, Japan, United Kingdom, France, Netherlands, Spain
Novartis Pharmaceuticals

Completed

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Acute Lymphoblastic Leukemia (ALL) | Chronic Myelogenous Leukemia (CML) | Metastatic Gastrointestinal Stromal Tumors (GIST) | Receptor Tyrosine Kinase (KIT) Mutated Melanoma

Italy, United Kingdom, Canada, Singapore, Netherlands, France, Korea, Republic of, United States, Slovakia, Hungary, Russian Federation, Hong Kong, Spain, Israel, Sweden, Austria
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

China, Korea, Republic of, Thailand
Agios Pharmaceuticals, Inc.

Recruiting

Pyruvate Kinase Deficiency Global Longitudinal Registry (PEAK Registry)

Pyruvate Kinase Deficiency

United States, Germany, Spain, Italy, United Kingdom, Czechia, France, Canada, Korea, Republic of, Netherlands, Turkey, Portugal, Denmark, Ireland, Switzerland, Thailand
Agios Pharmaceuticals, Inc.

Active, not recruiting

Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

Pyruvate Kinase Deficiency

United States, Spain, Japan, Canada, United Kingdom, Korea, Republic of, Ireland, Thailand, Italy, Turkey, Denmark, Brazil, France, Germany, Netherlands, Switzerland
Agios Pharmaceuticals, Inc.

Completed

A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

Anemia, Hemolytic | Pyruvate Kinase Deficiency

United States, Spain, Switzerland, Turkey, Germany, France, United Kingdom, Japan, Netherlands, Brazil, Canada, Czechia, Denmark, Italy, Korea, Republic of, Thailand
AstraZeneca
Hutchinson MediPharma (HMP)

Active, not recruiting

Savolitinib vs. Sunitinib in MET-driven PRCC.

Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Neoplasms by Site | Kidney Diseases | Carcinoma | Enzyme Inhibitors | Protein Kinase Inhibitors

United States, Italy, France, Korea, Republic of, Brazil, Russian Federation, Ukraine
Day One Biopharmaceuticals, Inc.

Recruiting

Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Melanoma | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Thyroid Cancer, Papillary | Pilocytic Astrocytoma | Bladder Urothelial Carcinoma | Non-Small Cell Adenocarcinoma | MEK Mutation | RAS Mutation | Pancreatic Acinar Carcinoma | RAF Mutation | CRAF Gene Amplification | RAF1 Gene Amplification and other conditions

United States, Canada, Korea, Republic of, Spain, Australia, Belgium, France
Eli Lilly and Company

Active, not recruiting

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

Urogenital Neoplasms | Prostatic Neoplasms | Neoplasm Metastasis | Enzyme Inhibitors | Antineoplastic Agents | Hormones | Physiological Effects of Drugs | Antineoplastic Agents, Hormonal | Androgens | Hormones, Hormone Substitutes, and Hormone Antagonists | Abiraterone Acetate | Steroid Synthesis Inhibitors | Cytochrome... and other conditions

China, Canada, France, United States, Australia, Czechia, Hungary, Spain, Germany, Japan, Taiwan, Netherlands, Turkey, Mexico, Belgium, Korea, Republic of, Argentina, Romania, United Kingdom, Italy, Israel, Brazil, Poland, Greece

Clinical Trials on Bruton's Tyrosine Kinase in Korea, Democratic People's Republic of

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations